Umoja Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02. Januar 2024 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T...
Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with Potent and Highly Durable Activity
11. Dezember 2023 13:30 ET
|
Umoja Biopharma, Inc.
Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec™ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell...
Umoja Biopharma Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
02. November 2023 09:43 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma Announces Opening of Development and Manufacturing Facility in Louisville, Colorado
19. Oktober 2023 10:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the...
Umoja Biopharma to Present at the 2023 Cell & Gene Meeting on the Mesa
05. Oktober 2023 14:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit
01. September 2023 12:30 ET
|
Umoja Biopharma, Inc.
Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (CAR) T cell generation in vivo after a single infusion of VivoVec particles Additional data to be...
Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
23. August 2023 10:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for cancers, today announced it will unveil preliminary...
Umoja Biopharma to Present at the 2023 BIO International Convention
31. Mai 2023 10:17 ET
|
Umoja Biopharma, Inc.
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematological cancers, today announced that...
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
17. Mai 2023 09:00 ET
|
Umoja Biopharma, Inc.
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity when used in combination with TumorTag™ technology in an in vivo model...
Umoja Biopharma to Present New Data at the American Society of Gene and Cell Therapy 26th Annual Meeting
03. Mai 2023 08:00 ET
|
Umoja Biopharma, Inc.
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid...